Cargando…
Modulating Antiangiogenic Resistance by Inhibiting the Signal Transducer and Activator of Transcription 3 Pathway in Glioblastoma
Determining the mechanism of treatment failure of VEGF signaling inhibitors for malignant glioma patients would provide insight into approaches to overcome therapeutic resistance. In this study, we demonstrate that human glioblastoma tumors failing bevacizumab have an increase in the mean percentage...
Autores principales: | de Groot, John, Liang, Ji, Kong, Ling-Yuan, Wei, Jun, Piao, Yuji, Fuller, Gregory, Qiao, Wei, Heimberger, Amy B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3660053/ https://www.ncbi.nlm.nih.gov/pubmed/23013619 |
Ejemplares similares
-
The therapeutic potential of inhibitors of the signal transducer and activator of transcription 3 for central nervous system malignancies
por: Heimberger, Amy B.
Publicado: (2011) -
MiR-181 Family Modulates Osteopontin in Glioblastoma Multiforme
por: Marisetty, Anantha, et al.
Publicado: (2020) -
New perspectives in glioblastoma antiangiogenic therapy
por: Popescu, Alisa Madalina, et al.
Publicado: (2015) -
Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice
por: de Groot, John F., et al.
Publicado: (2010) -
Serum microRNA profiling in patients with glioblastoma: a survival analysis
por: Zhao, Hua, et al.
Publicado: (2017)